Southern Health		REGIONAL ADULT PARENTERAL DRUG MONOGRAPH				
		GENERIC NAME digoxin immune fab (Ovine)				
Effective Date: De	ec 2012	CLASSIFICATION	OTHER NAMES	PAGE		
Revised Date: Mar 14 2018		Antidote for digoxin intoxication	DigiFab, Antidigoxin Fab Fragments	1 of 2		
ADMINISTRAT	FION PO	LICY:	•			
IV Injection -	Must be a	administered by a Physician				
IV Infusion -	Administ	ration restricted to nurse in ED	O/Cardiac Room/ICU. Continuous cardiac mon	itoring		
	required.					
	FION/DII	LUTION/ADMINISTRATIO	digoxin immune fab (Ovine) CLASSIFICATION Intidote for digoxin intoxication OTHER NAMES DigiFab, Antidigoxin Fab Fragments 1 of 2 PAGE 1 of 2 stered by a Physician restricted to nurse in ED/Cardiac Room/ICU. Continuous cardiac monitoring N/ADMINISTRATION: 0 mg vial. Gently mix each vial with 4 mL sterile water for injection. Store nreconstituted vials in 50 mL of normal saline and administer over at least 30 unutes. wer 30 minutes. May be given by rapid IV push if cardiac arrest is imminent. 0 mg/mL oxin to be neutralized. mplete vial 00unt: unt: calculate dose based on amount – 40 mg (one vial) is capable of binding 0.5 mg digoxin move after ingestion. atom ID Soe (number of vials) IV over 30 minutes move after ingestion. atom ID Soe (number of vials) IV over 30 minutes move after ingestion. atom ID Soe (number of vials) I Mover 30 minutes move after ingestion. atom ID Soe (number of vials) = (serum digoxin concentration (mmol per L) x 0.781 x weight (kg)) 100 ingested: Dose (number of vials) = 0.5 mg digoxin bound/vial 800 mg (20 vials) 800 mg (20 vials)			
Available as:		÷ •	· ·			
IV Intermittent:	:	Dilute reconstituted vials minutes.				
Maximum rate: Maximum conce	a concentration: 10 mg/mL					
DOSAGE:						
Usual:						
		t of digoxin to be neutralized.				
	-	ext complete vial	tan viala) Wavan 20 minutaa May ha nanaata	d anaa if		
• <u>Acute ingestion</u>	$0\Pi - \Pi K\Pi 0$	-	1.			
• <u>Acute ingestion – Known amount:</u> calculate dose based on amount – 40 mg (one vial) is capable of						
<u>Chronic inges</u>	stion (toxic					
• <u>Acute or chro</u>	onic ingesti			hours or		
• Dose based of	n serum co	more after ingestion. m concentration: Dose (number of vials) =				
		_	100			
	6 6					
Maximum single						
Maximum daily STABILITY/CO)			
	, , , , , , , , , , , , , , , , , , ,	/1//11/				
	•					
Stability of Fina	l Admixtı	use immediately				
Compatibility:	S DOTEN	Compatible with				
 PRECAUTIONS, POTENTIAL ADVERSE REACTIONS: SEVERE HYPOKALEMIA. Monitor potassium levels frequently during administration. 						
 SEVERE HTFORALEMIA. Monitor potassium levels nequentry during administration. Allergic reactions include anaphylaxis (rare) 						
 Anergic reactions include anaphylaxis (rare) If signs of anaphylaxis arise during administration the infusion should be discontinued and supportive measures instituted. Skin testing may be considered in high risk individuals. 						
 Congestive heart failure and arrhythmias have occurred due to digoxin withdrawal. 						

Approved by the Regional Pharmacy & Therapeutics Committee

	REGIONAL ADULT PARENTERAL DRUG MONOGRAPH GENERIC NAME digoxin immune fab (Ovine)			
Southern Sud				
Effective Date: Dec 2013	CLASSIFICATION	OTHER NAMES	PAGE	
Revised Date: Mar 14 2018	Antidote for digoxin intoxication	DigiFab, Antidigoxin Fab Fragments	2 of 2	
	ND NURSING CONSIDERA		. 1	
• Following administrati minutes or less.	on, improvement in signs and s	symptoms of digitalis intoxica	ation begins within 30	
	proximately 0.5 mg of digoxin ((or digitoxin)		
	nterferes with some digoxin ass	. .	inistration may be falsely	
• Patients with severe re	nal insufficiency potentially car	n develop recurrent digoxin to	oxicity due to displacemen	

• Patients with severe renal insufficiency potentially can develop recurrent digoxin toxicity due to displacement from fab fragments.